The research characterizes the molecular “cargo” of circulating extracellular vesicles in obesity and links the findings to human genetic approaches to identify potential therapeutic targets for metabolic disease.

Severe obesity — a condition of being 100 pounds or more overweight — has doubled in the United States over the past two decades to 9.2%, with the greatest increases among women and Latino populations.

An observational study found that bariatric surgery was associated with 63% reduced risk of Alzheimer's disease and related dementias.

Daniel Drucker, MD, a pioneering scientist whose research contributed to the development of the blockbuster GLP-1 medicines used to treat diabetes and obesity, was listed by TIME magazine as one of the 100 Most Influential People of 2024.

Researchers examined if childhood obesity could be prevented by leveraging a combination of health behavior counseling offered by pediatric primary care clinicians and modern digital health literacy tools.

The report supports previous clinical trials that found the GLP-1 receptor agonist drug semaglutide reduced kidney disease progression in patients with Type 2 diabetes.

The study reported in the journal Nature provides a mechanistic explanation for the “obesity paradox” — that obesity can contribute to cancer progression but also improve response to immunotherapy.